LV10182A - Mematinu satuross ciets farmaceitisks zalu veids ar paplasinatu divpakapju izdalisanas profilu un ta razosana - Google Patents

Mematinu satuross ciets farmaceitisks zalu veids ar paplasinatu divpakapju izdalisanas profilu un ta razosana

Info

Publication number
LV10182A
LV10182A LV931013A LV931013A LV10182A LV 10182 A LV10182 A LV 10182A LV 931013 A LV931013 A LV 931013A LV 931013 A LV931013 A LV 931013A LV 10182 A LV10182 A LV 10182A
Authority
LV
Latvia
Prior art keywords
solid pharmaceutical
razosana
mematin
drug
expanded
Prior art date
Application number
LV931013A
Other languages
English (en)
Other versions
LV10182B (en
Inventor
Eberhard Nuernberg
Erhard Seiller
Stefan Ritsert
Original Assignee
Merz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co
Publication of LV10182A publication Critical patent/LV10182A/lv
Publication of LV10182B publication Critical patent/LV10182B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LVP-93-1013A 1992-08-04 1993-08-04 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof LV10182B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4225730A DE4225730C2 (de) 1992-08-04 1992-08-04 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Publications (2)

Publication Number Publication Date
LV10182A true LV10182A (lv) 1994-10-20
LV10182B LV10182B (en) 1995-04-20

Family

ID=6464804

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-1013A LV10182B (en) 1992-08-04 1993-08-04 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof

Country Status (17)

Country Link
US (1) US5382601A (lv)
EP (1) EP0582186B1 (lv)
JP (1) JP3560244B2 (lv)
CN (1) CN1086708A (lv)
AT (1) ATE176866T1 (lv)
AU (1) AU669731B2 (lv)
CA (1) CA2141691C (lv)
DE (2) DE4225730C2 (lv)
DK (1) DK0582186T3 (lv)
ES (1) ES2128369T3 (lv)
GR (1) GR3030227T3 (lv)
IL (1) IL106580A (lv)
LT (1) LT3201B (lv)
LV (1) LV10182B (lv)
MX (1) MX9304675A (lv)
WO (1) WO1994003158A1 (lv)
ZA (1) ZA935614B (lv)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
AU3860797A (en) * 1997-07-16 1999-02-10 Antrin Research Limited Pharmaceutical formulations for oral administration
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5840334A (en) * 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
DE19809242A1 (de) * 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1852113A3 (en) * 2000-12-07 2008-03-12 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
EP1727538A2 (en) * 2004-02-13 2006-12-06 Neuromolecular Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
EP1734920A2 (en) * 2004-02-13 2006-12-27 Neuromolecular Inc. Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
ES2483126T3 (es) * 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
KR100901927B1 (ko) * 2004-06-17 2009-06-10 메르츠 파마 게엠베하 운트 코. 카가아 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP2008503475A (ja) * 2004-06-17 2008-02-07 フォーレスト ラボラトリーズ， インコーポレイテッド メマンチンの放出が改変された製剤
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588295C (en) * 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
JP5597343B2 (ja) * 2005-04-28 2014-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有する組成物
US20060270742A1 (en) * 2005-05-02 2006-11-30 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
DK1966611T3 (da) * 2005-12-23 2012-09-10 Alk Abello As Fremgangsmåde til opløsningstest af farmaceutiske produkter
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
US20080069961A1 (en) * 2006-09-14 2008-03-20 Halliburton Energy Services, Inc. Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
WO2009084017A2 (en) 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
US20140004189A1 (en) 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
US20130323309A1 (en) 2011-02-17 2013-12-05 Lupin Limited Sustained Release Composition of Memantine
TR201104108A2 (tr) 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salımlı memantin tablet.
FR2980973B1 (fr) * 2011-10-11 2013-11-15 Univ Clermont Auvergne Composition pour le traitement prophylactique de la douleur neuropathique.
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
MX2015001917A (es) 2012-08-16 2015-10-29 Teva Pharma Composiciones farmaceuticas de memantina.
EP2954009A1 (de) * 2013-02-08 2015-12-16 Basf Se Herstellung von anorganisch-organischen kompositmaterialien durch reaktive sprühtrocknung
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN117860718A (zh) 2017-08-24 2024-04-12 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US11602507B2 (en) 2019-05-27 2023-03-14 Trikona Pharmaceuticals Pvt. Ltd Extended release oral composition of memantine or its salt and its process for the preparation
CU24720B1 (es) 2020-11-24 2024-10-09 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
EP4678167A1 (en) * 2024-07-04 2026-01-14 Laboratorio della Farmacia S.p.A. Solid oral composition with gradual enteric release for lipophilic active ingredients

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB715874A (en) * 1952-10-03 1954-09-22 Horlicks Ltd A tablet for use in treating peptic ulcers
GB840091A (en) * 1955-09-08 1960-07-06 Upjohn Co Improvements in or relating to therapeutic compositions and the manufacture thereof
US3594467A (en) * 1968-10-09 1971-07-20 Richardson Merrell Inc Long-lasting troche
CH603545A5 (lv) * 1972-04-20 1978-08-31 Merz & Co
US4076846A (en) * 1974-11-22 1978-02-28 Sumitomo Bakelite Company Limited Protein-starch binary molding composition and shaped articles obtained therefor
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4419369A (en) * 1980-09-22 1983-12-06 Baylor College Of Medicine Protein mineral dietary module
US4346112A (en) * 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
EP0211294A3 (en) * 1985-08-06 1988-11-17 Eltech Systems Corporation Treating agent for liquid media
US4897380A (en) * 1985-08-30 1990-01-30 Pollack Robert L Method and composition for relieving dietary-related disorders
US4853377A (en) * 1985-10-15 1989-08-01 Pollack Robert L Method and composition for increasing production of serotonin
DK179687D0 (da) * 1987-04-08 1987-04-08 Farma Food As Praeparat
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
ES2059602T3 (es) * 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
WO1991006287A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
AU7991191A (en) * 1990-05-23 1991-12-10 Southwest Research Institute Filament system for delivering a medicament and method
FR2664499B1 (fr) * 1990-07-16 1994-11-04 Jacques Dubois Nouvelles formes pharmaceutiques, leur procede de preparation et leurs applications.

Also Published As

Publication number Publication date
CN1086708A (zh) 1994-05-18
EP0582186B1 (de) 1999-02-24
US5382601A (en) 1995-01-17
EP0582186A1 (de) 1994-02-09
IL106580A0 (en) 1993-12-08
CA2141691A1 (en) 1994-02-17
JPH07509479A (ja) 1995-10-19
LT3201B (en) 1995-03-27
DE4225730C2 (de) 2003-04-30
WO1994003158A1 (en) 1994-02-17
AU669731B2 (en) 1996-06-20
DK0582186T3 (da) 1999-09-27
IL106580A (en) 1998-02-08
DE59309388D1 (de) 1999-04-01
ATE176866T1 (de) 1999-03-15
ZA935614B (en) 1995-02-03
LTIP839A (lt) 1994-08-25
LV10182B (en) 1995-04-20
DE4225730A1 (de) 1994-02-10
MX9304675A (es) 1994-03-31
GR3030227T3 (en) 1999-08-31
AU4706993A (en) 1994-03-03
ES2128369T3 (es) 1999-05-16
JP3560244B2 (ja) 2004-09-02
CA2141691C (en) 2002-04-09

Similar Documents

Publication Publication Date Title
ZA935614B (en) Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof
BR0207005A (pt) Sistema de distribuição granular, processo para prepará-lo, uso do mesmo, produto ou composição flavorizado(a), e, produto ou composição perfumado(a)
FI942092A7 (fi) Hallitusti vapauttava valmiste
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
HRP20010243B1 (hr) Pripravci koji sadrže difosfonske kiseline
DE69637096D1 (de) Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen
DK0711151T3 (da) Partikler med modificerede fysisk-kemiske egenskaber, deres fremstilling og anvendelser
WO2004050058A3 (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CA2171303A1 (en) Active principles and gas containing microparticles
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
CA2106172A1 (en) Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
FI945912A0 (fi) Proteinoidikantajat ja menetelmät niiden valmistamiseksi sekä niiden käyttö
DE69314186D1 (de) Brausemischungen enthaltend ibuprofen und verfahren
AR021806A1 (es) COMPOSICIoN FARMACÉUTICA EN FORMA DE TABLETA QUE COMPRENDE ENTACAPONA Y MÉTODO DE PREPARACIoN.
HUP0003405A2 (hu) Szabályozott hatóanyag-leadású, szublingvális vagy bukkális adagolású gyógyszerkészítmények
DE68902531D1 (de) Dispergierbare zubereitung.
DE69622739D1 (de) Pharmazeutische zubereitung mit schneller freisetzung
CA2175470A1 (en) Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide
DE60017881D1 (de) Trinkbare pharmazeutische suspension von ibuprofen
GEP20043377B (en) Pharmaceutical Complex
CA2001568A1 (en) Medicament for treating toxoplasmosis
IE890275L (en) Pharmaceutical composition for 4-aroylimidazol-2-ones
TH47888A (th) องค์ประกอบที่ประกอบด้วยกรดไดฟอสโฟนิค
TH59782A3 (th) สารผสมของกาแลนแทมีนชนิดปลดปล่อยที่มีการควบคุม
GT198800030A (es) Un producto para la preparacion de un azol.